Show an ad over header. AMP

I am the second

AstraZeneca issues new Phase 3 data for COVID vaccine, confirming safety and efficacy

AstraZeneca said Wednesday that a primary analysis of its Phase 3 trial data confirmed its coronavirus vaccine's "safety" with a 76% efficacy rate against symptomatic COVID.

Flashback: The company reported on Monday that a U.S. trial found its vaccine 79% effective, but faced backlash after NIAID said Tuesday it may have included information that provided an "incomplete view of the efficacy data" in its U.S. results.

Keep reading...Show less

Related Articles

Insights

mail-copy

Get Goodhumans in your inbox

Most Read

More Stories